期刊
DRUG RESISTANCE UPDATES
卷 11, 期 6, 页码 210-218出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.drup.2008.09.002
关键词
Notch; Gamma-secretase inhibitor (GSI); Hematological malignancies; T-ALL; Multiple myeloma; B-cell malignancies
资金
- NCI NIH HHS [R01 CA130923-01A1, R01 CA130923] Funding Source: Medline
Activation of Notch signaling has been implicated in pathogenesis of various hematologic tumors including leukemias, lymphomas, and multiple myeloma. Pre-clinical studies have suggested that inhibition of Notch could be an attractive new approach to treatment of hematologic malignancies. This review discusses most recent findings in the field and potential role of Notch signaling as a therapeutic target focusing on the effects of gamma-secretase inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据